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Abstract 
 
Vincristine is one of the core chemotherapy agents used in the treatment of pediatric acute 
lymphoblastic leukemia (ALL). However, one of the major toxicities resulting from vincristine exposure 
is vincristine-induced peripheral neuropathy (VIPN). When VIPN results in significant morbidity, the 
vincristine dose may need to be reduced, thus potentially decreasing the effectiveness of treatment. 
To date there are no robust biomarkers used clinically to determine which patients will be at risk for 
worse neuropathy. The current study included genome wide association analyses in two independent 
cohorts: Pediatric Oncology Group (POG) ALL trials and a multicenter study based at Indiana 
University in children with ALL. A meta-analysis of the cohorts identified two SNPS, rs1045644 and 
rs7963521, as being significantly (p-value threshold 0.05/4749 =1.05E-05) associated with 
neuropathy. Subsequently these SNPS may be effective biomarkers of VIPN in children with ALL. 
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INTRODUCTION 
 
Leukemia is the most commonly diagnosed pediatric cancer (ages 0-19: 26% of pediatric cancers) 
with acute lymphocytic leukemia (ALL) being the most common subtype (75%)1. Due to improved 
multidrug treatment regimens developed over the past 40 years, the 5-year survival rate for pediatric 
ALL has increased from 57% to 90%1. Vincristine is one of the core chemotherapeutic agents used in 
the standard multidrug treatment plan1. However, due to vincristine exposure, approximately 78% of 
these children develop clinically significant neuropathy (Vincristine-Induced Peripheral Neuropathy: 
VIPN) 2. The development of VIPN is characterized by progressive motor, sensory and autonomic 
nerve dysfunction3-5 and may result in vincristine dose reductions during treatment which increase 
risk for an overall loss of therapeutic efficacy. 
 
 
Vincristine is metabolized by the cytochrome P450 CYP3A family of phase I drug-metabolizing 
enzymes6. Previous work from our laboratory revealed that children with the active form of the 
CYP3A5 (high CYP3A5 protein expresser genotype) had a 5-fold greater clearance of the drug and 
experienced less VIPN than the CYP3A5 low expressers. Furthermore, subjects in the CYP3A5 high 
expresser genotype group had lower neuropathy scores over the course of ALL treatment6,7. In 
addition, low expressers experienced more persistent neuropathy after completion of vincristine 
therapy8. Further studies have demonstrated it is specifically the CYP3A5*1 allele which allows for 
expression of the active CYP3A5 enzyme. As such, in our prior study, subjects carrying at most one 
CYP3A5*1 allele (CYP3A5 high expressers) are less likely to experience severe VIPN9. 
 
The development of VIPN not only jeopardizes therapy, but also may negatively affect the function 
and quality of life for children long after the completion of treatment10-12. Ness and colleagues 
evaluated a large cohort of adult survivors of pediatric cancer and found that exposure to vincristine 
during childhood was associated with a higher risk for motor impairment later in life13. Motor Au
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impairment can lead to decreased physical activity, obesity, type 2 diabetes, metabolic syndrome and 
cardiovascular disease14-17. A recent study by Ou et al. (2017) found that pediatric survivors 5 – 10 
years post ALL diagnosis and only receiving chemotherapy had significantly more hospitalizations 
after completion of ALL treatment than that of the general population18; thus suggesting the presence 
of late effect health burdens in cancer survivors. 
 
 
Since the survival rate is so high and the long-term sequlae of vincristine exposure so prevalent in 
children with ALL, it is imperative that we elucidate the key factors underlying the vulnerability of 
some children to develop severe and/or persistent neurotoxicity. This is an important step toward not 
only maximizing efficacy but also minimizing toxicities in the treatment of pediatric ALL. In this study, 
we conducted a genome wide association analysis to investigate genetic biomarkers in two vincristine 
treated cohorts of children with preB ALL. 
 
 
RESULTS 
 
 
POG GWAS Analysis 
Starting with 1696 patients from POG 9904 and 9905 studies, 1103 patients were classified as 
Caucasian based on the population stratification classification using the GWAS data. Genotype data 
quality control (QC) analysis required a minimum sample call rate of 95%, a minimum SNP call rate of 
95%, a Hardy-Weinberg p value > 0.0001, and a minor allele frequency > 0.05. This QC analysis 
reduced the total number of SNPs to 587,014 among 1068 patients. The overlapping POG GWAS 
SNPs with the ADVANCE Trial GWAS SNPs further reduced the number of SNPs to 4,749. A consort 
plot (Figure 1) summarizes these data filtering steps. Bonferroni correction for multiple comparisons 
with this number of SNPs requires a p value of 0.0000105 for genome wide significance (0.05/4749). 
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Among these 1068 patients, 4.8% of patients experienced NCI CTCAE grade 3 or higher neuropathy 
(See Table 1b). As gender was not associated with the time to onset of grade 3 or 4 neuropathy, the 
GWAS was analyzed in a univariate SNP association analysis. POG GWAS Manhattan plots (Figure 
2a) revealed only one SNP, rs7792939, meeting the minimum genome wide association level for 
significance (p = 2.39E-06). Patients with one or more copies of the minor allele for this SNP incurred 
a hazard ratio of 2.83 for developing grade 3 or 4 neuropathy (95% CI (1.82, 4.39). 
 
 
 
ADVANCE Trial GWAS Analysis 
The ADVANCE trial had data from 99 eligible patients available at the time of this GWAS analysis. 
After population stratification classification, 70 Caucasian patients were selected for inclusion in this 
analysis. The QC analysis required a minimum sample call rate of 90%, a minimum SNP call rate of 
90%, a Hardy-Weinberg p value > 0.001, and a minor allele frequency > 0.05. It reduced the number 
of SNPs to 26,825. The overlapping SNPs between the genotyping platforms utilized in the POG and 
ADVANCE cohorts further reduced the number of SNPs for analysis to 4,749. The consort plot 
(Figure 1) summarizes these data filtering steps. 
 
 
Among these 70 patients, 46% were male and 54% were female (see Table 1); the average age was 
 
8.2 years (SD = 4.7), which ranged from 1 to 19 years; the average Total Neuropathy Score-pediatric 
Vincristine (TNS-PV) 5-item neuropathy score during the first 12 months of vincristine treatment was 
3.78 (SD = 2.61) and ranged from 0 to 11; the maximum 5-item neuropathy score during the first 12 
months was 6.95 (SD = 4.11) and ranged from 0 to 20. Neither gender nor age was associated with 
the average or maximum neuropathy score. None of the 4,749 SNPs showed significance in 
predicting either the average or maximum neuropathy scores. In particular, the SNP, rs7792939, 
which showed significance in the POG trial data analysis, was not significant (p = 0.37) in the 
ADVANCE trial (Figure 2b). Au
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Integrated GWAS Analyses 
Two integrated GWAS analyses were conducted to test and validate the SNPs in their associations 
with the neuropathy among the two study populations. The first one was a meta-analysis, in which the 
association test statistics from the two studies (POG trials and ADVANCE trial) were weighted by 
their standard errors, and summarized into one statistic. The meta-analysis was conducted based on 
the same genetic model (additive or dominance), and the same direction of SNP effects between two 
studies. In addition, the statistics of two different neuropathy scores (average and max) from the 
ADVANCE Trial were integrated with the statistics of the POG neuropathy phenotype separately. 
Using the same genome wide p-value threshold 0.05/4749 =1.05E-05, we identified two SNPs that 
reached the genome-wide significance level (Table 2). The meta-statistics comparing the average 
ADVANCE Trial neuropathy and POG neuropathy scores showed SNP rs1045644 had a dominance 
effect with a p-value = 2.36E-06. This SNP rs1045644 effect remains significant (p-value = 3.78E-06) 
after multivariate analyses of both SNPs, rs1045644 and rs7963521.  Both additive and dominance 
genetic model meta-analyses evaluating maximum ADVANCE Trial neuropathy and POG 
neuropathy scores were statistically significant, p = 8.66E-06 and 8.65E-07, respectively. In 
particular, in the POG trials, rs1045644 subjects with one or two copies of the minor allele 
(G=0.4113: 1000 Genomes) had a protective effect against developing neuropathy. These subjects 
had a hazard ratio of 0.27 (exp(-1.28) = 0.27) for developing grade 3 or 4 neuropathy compared to 
subjects with two major alleles (95% CI 0.16, 0.50). In the ADVANCE Trial, patients with one or two 
copies of the minor allele for the same SNP rs1045644 had significantly lower maximum neuropathy 
scores than subjects with two major alleles (3.56 units smaller, 95% CI -5.45, -1.67).  
The other SNP showing genome wide significance was rs7963521. In this case, only the additive 
meta-analysis for maximum neuropathy scores for both the ADVANCE Trial and the POG trials were 
statistically significant, p = 1.05E-05. A second copy of rs7963521 minor allele (c=0.3822: 1000
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Genomes) led to increased risk of grade 3 or 4 neuropathy in both study populations (POG Trial: HR 
2.23 (1.49, 3.35); ADVANCE Trial: HR 2.16 (0.53, 3.70). Taking two SNPs together, rs1045644 and 
rs7963521, into the multivariate analysis and meta-analysis, rs1045644 remains significant (p-value = 
3.78E-06). In the ADVANCE trial, both SNPs can predict 26% of variation in the VIPN among patients. 
 
 
In a second meta-analysis, top SNPs were first selected from the POG GWAS; and only the top 
SNPs were validated in the ADVANCE Trial. This testing and validation analysis was only conducted 
within the same genetic model. In selecting the top three SNPs from the POG Trial GWAS, only 
rs1045644 was validated in the ADVANCE trial, wherein the p-value was less than 0.05/3 = 0.017 
(see Table 2). All the other testing and validation SNP selection strategies led to the same results. 
 
 
DISCUSSION 
 
Treatment for ALL pediatric patients includes vincristine as part of the standard multidrug plan1. 
However, due to vincristine exposure, approximately 78% of these children will develop VIPN2. Even 
though many of these children will recover from VIPN, there is a subgroup who will continue to 
experience long-term effects well into adulthood19.  Furthermore, there are significant concerns that 
late effects or chronic effects of cancer treatment, such as irreversible neuropathy, may be associated 
with decreased physical activity, which may ultimately increase the risk of obesity in cancer survivors 
as well as a multitude of downstream negative health effects.20 As such, developing therapeutic 
approaches that avoid neuropathy in children at highest risk for neuropathy, particularly those with 
lower risk cancers, is crucial to optimizing long term outcomes in survivors of childhood cancers.  The 
best possible solution is to find a chemotherapy agent that avoids neuropathy; however, until one is 
developed and successfully incorporated into care for childhood ALL, it is critical that we elucidate the 
key factors underlying the vulnerability of some children to significant neuropathy.  This may 
ultimately allow eliminating or decreasing vincristine dosing in children at highest risk for severe 
neuropathy, particularly in those with low risk disease. 
 
The objective of the current study was to utilize the patients from our limited institution ADVANCE trial 
as a validation cohort for a larger POG population in a genome wide association study for vincristine- 
induced peripheral neuropathy. The results from the meta-analysis for the ADVANCE and POG trials 
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revealed two SNPs, which met genome wide significance for association with the maximum TNS in 
year 1, but only in the additive model. The first SNP was rs1045466, located on chromosome 14 and 
part of the coagulation factor C homology (COCH) gene. The second SNP was rs7963521, located 
on chromosome 12 and associated with the regulation of chemerin plasma levels21. 
Specifically, rs1045466 is part of the COCH gene which encodes the secreted protein cochlin22 and is 
associated with progressive hearing loss and vestibular imbalance23. It appears that a disruption in 
this gene can lead to loss of cellularity and aggregation of acellular esosinophilic deposits in the 
cochlear and vestibular labyrinths. Also, there is aggregation of cochlin in the areas which normally 
express the protein23. These deficits can begin to appear at any time in adulthood: early or late24. 
 
Although similar to the characteristics of Meniere’s Disease, the current literature shows that this 
gene does not appear to be involved in risk for developing Meniere’s25 and is a syndrome unto itself. 
In a large retrospective study of childhood cancer survivors, Oeffinger and colleagues found that 
survivors had a relative risk of 6.3 (3.3 – 11.8) compared to their healthy siblings for developing 
severe or disabling hearing loss which was not correctable with the use of an aid. Although, it is not 
clear how many of the cases were in individuals treated with vincristine, the demographics do show 
that 29.5% of the surveyed population had a diagnosis of leukemia26. Another large more recent 
study found similar results of hearing loss in survivors as compared to their peers27. Our findings 
regarding SNP rs1045466 and the role it plays in deafness provides us with a clear starting point to 
find a potential biomarker for predicting which survivors of childhood cancers may develop severe 
hearing loss. Furthermore, cochlin is involved in embryonic stem cell self-renewal via stimulation by 
Bone Morphogenetic Protein (BMP). More importantly, if overexpressed, cochlin can substitute for 
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BMP28. This is a key point as BMP plays critical roles throughout neural stem cell maturation and 
neurogenesis well into adulthood29. In a recent study by Heggeness and colleagues (2017), they 
demonstrated that direct injection of BMP into a mouse model of sciatic injury could induce marked 
proliferation of previously quiescent cells within peripheral nerves30.  Given our findings which show 
SNP rs1045466 is associated with lower neuropathy scores in our subjects, we hypothesize that the 
cochlin protein is being overexpressed and facilitating recovery from the toxicity of vincristine. 
Mechanistic studies linking cochlin expression to VIPN should be considered. 
 
 
 
The second SNP, rs7963521, is located on chromosome 12 and is associated with plasma/serum 
levels of Chemerin21. Chemerin is a versatile protein which acts on the chemokine like receptor 1, G 
protein-coupled receptor 1 and the C-C chemokine-like receptor2 31,32. Depending on how the protein 
is processed from its preprochemerin form, it can be involved in angiogenesis33, adipogenesis34, 
osteoblastogenesis35 diabetes36 or inflammatory processes37-39. It is clear that many of these 
processes, if disrupted from normal functioning, could lead to long-term or chronic disorders. Findings 
from the pediatric cancer survivor studies mentioned previously indicate that many survivors have 
long-term disorders associated with these physiologic pathways26,27. It is possible that, in the setting 
of chemotherapy induced peripheral neuropathy, the impact of variability in chemerin levels could 
lead to impaired myelin repair via the role chemerin plays in adipogenesis. Specifically, chemerin is 
involved with cell differentiation of preadipocytes into adipocytes55. Subsequently in the presence of 
growth factors, adipocytes can differentiate into Schwann cells which re-myelinate peripheral 
nerves40. Additionally, chemerin levels have been identified as an independent predictor for 5-year 
mortality in other types of cancers such as gastric cancer41. Thus, in addition to being a predictor of 
long-term sequelae of chemotherapy treatment, SNP rs7963521 may also be useful as a predictor of 
long-term survival for pediatric cancer patients. 
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Diouf et al. (2015) found that a single-nucleotide polymorphism (SNP) in the CEP72 gene, which is 
involved in microtubule formation, is also associated with VIPN in children with ALL42. However, in our 
current study, this SNP was not associated with severe VIPN in either of our independent cohorts. 
Our findings are consistent with those of Gutuerrez-Camino et al43, who also did not find an 
association with CEP72 in pediatric ALL patients. The difference in our results may be due to the use 
of the TNS-5-item TNS©-PV as the main measure of our neuropathy score as  compared to the NCI 
CTCAE© V.4.0 scale. The TNS-5-item TNS©-PV is a more granular neuropathy assessment tool, 
and it is likely the subpopulation of patients with ALL we used for analysis was phenotypically 
different. 
 
 
Overall, the GWAS results provide two biologically interesting SNPs that may be useful as biomarkers 
for prediction of severe VIPN in children with ALL. The next critical step will be to elucidate the 
functional consequences of these SNPs as well as to understand their potential relevance in 
predicting risk for irreversible VIPN in pediatric cancer survivors. This understanding will be important 
in optimizing long-term outcomes of survivors of childhood cancer as well as beginning to move 
toward individualized treatment strategies based on risk of disease and risk for significant neuropathy. 
Limitations 
The main limitation of this study is that neuropathy assessments varied in the POG and ADVANCE 
samples. The NCI CTCAE© v.2.0 was used as the primary tool for quantifying VIPN in the POG 
studies. Yet, the CTCAE© has been criticized as a neuropathy assessment measure due to concerns 
regarding limited inter-rater reliability and floor effects which result in most scores falling in the low 
range (CTCAE 1 or 2). Thus, although the CTCAE© can underestimate neuropathy severity, we 
attempted to compensate for this concern by using CTCAE© scores ≥ 3 as indicative of severe 
neuropathy. Secondly, CTCAE and 5-item TNS©-PV scores are not directly comparable because 
TNS-based scores arise from validated, standardized neurologic assessment procedures and scoring 
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criteria.44,45 However, we justify our comparisons based on our prior work that demonstrates 
moderately strong correlations among TNS©-PV scores and CTCAE© sensory (r = 0.52) and motor 
scores (r = 0.48)44. Given these correlational data, and that the CTCAE was the only neuropathy 
measure available from the POG studies, use of data from these two different neuropathy measures 
is justified. 
 
 
METHODS 
 
Patients 
 
 
Pediatric Oncology Group Studies 9904 and 9905 
DNA samples were analyzed from patients enrolled in the Pediatric Oncology Group (POG) trials 
P9904 and P9905. A total of 1696 children with precursor B cell acute lymphoblastic leukemia were 
included in the initial sample set.  The purpose of POG 9904 and 9905 trials was to compare the 
efficacy of short and long infusion times of methotrexate with or without multidrug intensification. 
Patients received 18 to 23 doses of vincristine (1.5mg/m2 per dose) depending on study arm over the 
 
course of treatment along with other standard chemotherapy agents used in the treatment of 
childhood ALL. The complete treatment duration was 2.5 years from the date of diagnosis and 
patients remained on the study until completion, relapse or death. The data for these studies was 
frozen as of 9/30/2011. For the purposes of this neuropathy focused study, patients with the following 
conditions were excluded: Down’s syndrome, Charcot Marie Tooth disease, baseline peripheral 
neuropathy, and history of liver disease with chronic elevation in serum liver transaminases and 
bilirubin to greater than 5-times the upper limit of normal based on normal values for age. 
 
 
ADVANCE Trial 
 
The ADVANCE Trial was a four-institution study with the goal to validate previous findings that 
children expressing the CYP3A5 genotype develop less severe VIPN as compared to non- 
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expressers, as well as, evaluating for other potential predictors of VIPN. In summary, children with 
newly diagnosed precursor B-cell ALL (N=99) were recruited from four academic medical centers: 
Indiana University School of Medicine/Riley Hospital for Children, the University of Michigan 
Comprehensive Cancer Center/Mott Children’s Hospital, Vanderbilt University Medical 
Center/Monroe Carell Jr. Children’s Hospital, and George Washington University/Children’s National 
Medical Center. Participants were between the ages of 1 and 18 at the time of diagnosis and 
received vincristine according to Pediatric Oncology Group (POG) treatment trials (including: POG 
studies 9904 and 9905).  The standard vincristine dosage received was 1.5 mg/m2 (capped at 2-mg 
 
maximum dose).  Toxicity-based dose modifications were defined according to the specific POG 
protocol guiding the individual child’s leukemia treatment.  Patients were excluded if they had any of 
the following criteria: baseline peripheral neuropathy score greater than grade 1 per the NCI 
CTCAE© version 4.0; currently receiving erythropoietin, itraconazole, or vitamin supplement greater 
than 100% of the recommended daily allowance; Down’s syndrome; pregnancy; or a history of 
coexisting serious illness that would limit neurological assessments. All procedures were reviewed by 
the Indiana University Internal Review Board and approved (protocol #1105005420). 
 
 
Combined Meta analysis 
 
Initially each group was analyzed separately utilizing their maximal neuropathy score during the first 
year – NCI CTCAE for the POG patients and TNS©-PV for the ADVANCE trial patients. The overlap 
in SNPs between the groups was examined for those that had the same minor and major allele. The  
p value from each group was combined using the equation below. This allowed for a comparison 
between the two groups regardless of neuropathy assessment tool utilized.
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. 
 
Equation: �~ �1×���1+�2×���2��12×��12+�22×��22. 
 
Neuropathy Phenotype 
 
Pediatric Oncology Group Studies 9904 and 9905
 
 As part of the required clinical trial adverse event 
monitoring, children enrolled on the POG trials were clinically assessed by physical examination for 
peripheral neuropathy by their treating oncologists throughout treatment at each clinic visit. Based on 
National Cancer Institute Common Terminology Criteria for Adverse Events, version 2.0 (CTCAE 
v2.0), the vincristine induced neuropathy (VIPN) events are defined when patients experienced 
symptomatic neurotoxicity with neuropathy grade ≥ 3 in either motor or sensory neurons. 
 
ADVANCE Trial 
 
Vincristine induced neuropathy was assessed weekly for the first month of ALL treatment, followed by 
monthly for the remainder of the first year, followed by quarterly for the duration of ALL treatment 
using the Total Neuropathy Score (TNS©), NCI CTCAE© V.4.0, and the Modified “Balis” Pediatric 
Scale of Peripheral Neuropathy©45.  We used a TNS© variant the TNS – Pediatric Vincristine (PV) - 
revised and validated by our team for use in children receiving vincristine (TNS©-PV)44.  VIPN- 
 
associated pain was measured using the Pediatric Neuropathic Pain Scale©–Five (PNPS©-5).  The 
FACES© pain scale46,47 was used to assist children to select a PNPS©-5 pain severity rating. If the 
child did not understand a question, parents/guardians estimated the pain scores based on 
observations of their children.  Based on our previous findings of the five TNS items most associated 
with VIPN44, a 5-item total neuropathy score (TNS©-PV) was used to summarize the VIPN in this 
genetic association data analysis. The 5-item score includes sensory symptoms (i.e., numbness, 
tingling, neuropathic pain), temperature sensibility, vibration sensibility, strength, and tendon 
reflexes. TNS and PNPS©-5 scores were assigned by trained evaluators. Neuropathy assessment 
training was completed as previously described44.  NCI-CTCAE neuropathy scores were assigned 
by treating oncologists and advanced practice providers as part of clinical care. Medical caregivers 
and trained neuropathy evaluators were blinded to each other’s neuropathy scores. 
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Sample Genotyping 
 
 
Pediatric Oncology Group Studies 9904 and 9905 
POG ALL Trial Genotyping 
 
DNA (500ng) was digested with restriction enzymes, amplified, labeled, and hybridized to the 
Affymetric GeneChip Human Mapping 6 set for P9904 and 9905. The genotypic data used for 
analysis are in the Plink format, which includes genotype calls and on-calls for each SNP per sample. 
 
 
 
ADVANCE Trial 
DNA (750ng-1500ng) was amplified, fragmented, precipitated, and hybridized to the Human Exome 
Bead Chip at the Center for Inherited Disease Research at Johns Hopkins University. The genotypic 
data used for analysis are in the Plink format, which includes genotype calls and on-calls for each 
SNP per sample. 
 
 
Genotype Quality Control Analysis 
 
Quality control (QC) was performed to remove both samples and markers, which were unreliable 
using the criteria described in this section. Samples with >5% missing rate were excluded. 
Furthermore, SNPs with a study-wide missing data rate of >5% and/or evidence of Hardy-Weinberg 
disequilibrium (p≤ 0.0001) were discarded. SNPs with minor allele frequency (MAF) of <0.05 were 
also removed from the analysis because previous studies have shown that these SNPs have little 
power to detect association and are more prone to genotypic errors resulting in false positive 
evidence of association (see figure 1). PLINK was utilized to manipulate the data by generating both 
per sample and per SNP metrics to assess the quality of the genotypic data48. Upon completion of 
the quality control assessment, the final patient sample number for analysis was 1068. Au
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GWAS Analysis 
 
A principal components approach was applied to correct for any population stratifications49. Using the 
first two principle components, the Caucasian patient samples were selected for GWAS analysis. 
In the POG trials, the association between genotype and the time to the first neuropathy event 
(neuropathy grade ≥ 3 in either motor or sensory neurons) was analyzed through the Cox proportional 
hazard regression model. In the ADVANCE Trial, the association between genotypes and neuropathy 
scores was analyzed through linear regression.  Other clinical, demographic, and population 
stratification variables (i.e. genomic data derived race) were tested as covariates in the regression 
analyses. The genetic effect of any individual SNP was tested in dominant and additive (gene-dose) 
models. These analyses were performed in R coxph and lm packages50. Both univariate and multi-
variate analyses were conducted. The corresponding p-value of each SNP was summarized 
across chromosomes in Manhattan and QQ plots. Genetic analysis was only conducted among 
SNPs included in genotyping platforms utilized in both the POG trials and the ADVANCE Trial. A 
meta-analysis was implemented between two sets of genetic association analysis results. In this 
meta-analysis, the directionality of the SNPs was first confirmed by the minor allele frequency. The 
summary statistics was a weighted mean of two regression coefficients by their corresponding 
standard errors, respectively. The Bonferroni correction was used to justify the genome wide 
significant p-values. Furthermore, in multivariate analysis of ADVANCE trial data, the R-square of 
the SNP combination predictive effect on VIPN is reported. 
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STUDY HIGHLIGHTS 
 
What is the current knowledge on the topic? 
 
There are limited published data on validated genomic predictors of chemotherapy induced 
peripheral neuropathy and none published with the comprehensive and validated phenotyping that 
was accomplished in this study. 
What question did this study address? 
 
What genetic mutations are associated with vincristine induced peripheral neuropathy in children 
with ALL. 
What does this study add to our knowledge? 
 
The results from this study provide two additional therapeutic targets for addressing neuropathy in 
children diagnosed with ALL and receiving vincristine. 
How might this change clinical pharmacology or translational science? 
Neuropathy has a significant impact on the health trajectory of the children with ALL and developing 
novel treatments to alleviate or eliminate this side effect would greatly increase the quality of life for 
these survivors. Furthermore, having the ability to predict children at highest risk for significant 
neuropathy could eventually provide an opportunity for balancing disease risk with risk for severe, 
irreversible adverse side effects to optimize outcomes in kids with curable cancers. 
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Legends 
 
Table 1. Demographic variable and neuropathy score for POG and ADVANCE Trial 
 
Table 2. POG and ADVANCE Neuropathy P-Values 
 
Figure 1. Patient and SNP selection flowchart for POG and ADVANCE Trial 
Figure 2a. Manhattan plot and Quantile-Quantile plot for POG study. 
Figure 2b. Manhattan plot and Quantile-Quantile plot for ADVANCE Trial 
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Table 1. Demographic variable and neuropathy score for POG and ADVANCE 
Trial 
 
 
  
Total Sample 
ADVANCE Trial Sample (N) 63 
POG Sample (N)  1068 
   
Age – ADVANCE Trial - 
only 
Mean (SD) 8.22 (4.68) 
Range 1-19 
 
  
Gender   n (%) 
ADVANCE Trial Male  29 (46.0) 
POG Male 559 (52.3) 
ADVANCE Trial Female  34 (54.0) 
POG Female 509 (47.7) 
   
ADVANCE Trial -only 
TNS 5-item score  
(12 month average) 
Mean (SD) 3.78 (2.61) 
Range 0-11 
ADVANCE Trial - only 
TNS 5-item score  
(12 month maximum) 
Mean (SD) 6.95 (4.11) 
Range 0-20 
   
POG – only 
CTC neuropathy event 
 n (%) 
NE = 3,4 51 (4.8) 
NE = 2,3,4 87 (8.1) 
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 Table 2. POG and ADVANCE Neuropathy P-Values 
  
 
 
rs1045644 
 
rs7963521   
   Study POG ADVANCE POG and ADVANCE Combined 
 
POG ADVANCE POG and ADVANCE Combined   
   Sample Size (n) 1065 63     1046 63     
   Minor Allele Frequency 0.38 0.33 --- 
 
0.41 0.43 ---   
   Average in Year 1 (ADD)                 
   p-value 7.32E-05 2.15E-03 1.85E-05   1.02E-04 1.32E-02 2.56E-05   
   Effect Size -1.02 -1.48     0.80 1.26     
   95% CI [-1.52,-0.51] [-2.40,-0.56]     [0.4,1.21] [0.27,2.25]     
   Average in Year 1 (DOM) 
 
      
  
   p-value 1.72E-05 3.33E-04 *2.36E-06 
 
7.82E-03 2.69E-03 2.92E-03   
   Effect Size -1.28 -2.28 
 
 
1.03 2.133 
 
  
   95% CI [-1.86,-0.69] [-3.48,-1.08] 
 
 
[0.27,1.78] [0.77,3.50] 
 
  
  
 
 
       
  
   Maximum in Year 1 (ADD)                 
   p-value 7.32E-05 1.79E-03 *8.66E-06   1.02E-04 6.57E-03 *1.05E-05   
   Effect Size -1.02 -2.36     0.80 2.161     
   95% CI [-1.52,-0.51] [-3.80,-0.91]     [0.4,1.21] [0.63,3.70]     
   Maximum in Year 1 (DOM) 
 
      
  
   p-value 1.72E-05 3.80E-04 *8.65E-07 
 
7.82E-03 2.66E-03 1.69E-03   
   Effect Size -1.28 -3.56 
 
 
1.03 3.36 
 
  
   95% CI [-1.86,-0.69] [-5.45,-1.67] 
 
 
[0.27,1.78] [1.21,5.50] 
 
  
                    
  
 
 
       
  
   The 5 item TNS©-PV score includes sensory symptoms, temperature sensibility, vibration sensibility, strength, and tendon reflexes.  The POG and ADVANCE   
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Combined Score is the combined p-values from the COG and ADVANCE 5-item TNS©-PV score. 
  
   Abbreviations: CI, confidence interval; ADD, additive model; DOM, dominant model 
 
   
  
   * indicates sample statistically significant after meta analysis        
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Pediatric Oncology Group               ADVANCE Trial 
 
 
 
 
 
 
 
 
 
 
 
 
P9904/P9905
N=1696
•Population 
Stratification
Caucasian
N=1103
•Sample call 
rate 95%
909,622 SNPS
N=1068
•SNP call rate 95%
•MAF>0.05
•HW p>0.0001
587,014 SNPS
N=1068
N=99
•Population 
Stratification
Caucasian
N=70
•Sample call 
rate 95%
247,451 SNPS
N=70
•SNP call rate 95%
•MAF>0.05
•HW p>0.0001
•With 5-items TNS score
26,841 SNPS
N=63
POG AT
4,749 SNPS 
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